cyrilzakka/clinical-trials huggingface dataset:
Effectiveness of Nebulized Hypertonic Saline and Epinephrine in Hospitalized Infants With Bronchiolitis

Acute bronchiolitis is the main cause for respiratory illness that requires hospitalization in children younger than 2 years. In the United States it has been shown that the burden of the disease is considerable, having an annual cost of more than $ 500 million and being responsible for the 17% of all infant hospitalizations . Aim of the present study was to verify the effects of nebulized 3% saline solution in comparison to normal saline in addiction to epinephrine in a large population of RSV positive cases of bronchiolitis; all patients presented a disease as much as severe to require hospitalization.The main study endpoints were the length of stay in hospital and the clinical response.

Among 136 patients assessed within 12 hours for entry into the study, 109 (69 males) accepted to participate, gave an informed consent and were randomly assigned either to receive every 6 hours the nebulized 0.9% saline (NS) (group I) or the 3% HS (group II) in addition to aerosolized epinephrine (1.5 mg) and to the conventional treatment (oxygen, fluids). Patients were randomized to receive different saline treatments using a computer-based randomization program. Study solutions, prepared by the local hospital pharmacy, were blinded to participants and investigators. Each treatment was delivered by a nebulizer with continuous flow of oxygen at 6 L/min through a tight-fitting facemask.

The main study endpoints were the length of stay (LOS) in hospital and the clinical response. LOS in hospital was defined as the time between study entry (within 12 hours of admission to the hospital) and the time at which the infant was discharged on the basis of the clinical grounds by the attending physician. Clinical response was determined using daily CSS evaluation; furthermore, the CSS was evaluated every day before and 30 minutes after nebulisation.

Eligibility Criteria:
Inclusion Criteria:

* children aged less than 2 years old
* clinical diagnosis of bronchiolitis

Exclusion Criteria:

* cardiac or pulmonary diseases
* premature birth \< 36 weeks of gestational age
* previous diagnosis of asthma
* an initial oxygen saturation of 85%
Effects of Resistance Training Preconditioning on Skeletal Muscle Recovery From a Period of Disuse in Young Adults

The goal of this clinical trial is to compare the effects of resistance training (RT) preconditioning vs no training on disuse-induced atrophy and post-disuse resistance training in young healthy individuals. The main questions it aims to answer are:

* To determine if performing RT prior to a period of disuse enhances the regain of strength, skeletal muscle size, and skeletal muscle quality while performing RT after a period of disuse.
* To determine if performing RT prior to a period of disuse dampens the maladaptive effects of disuse on muscle size, muscle quality, and strength.
* To determine the anabolic and proteolytic mechanisms underpinning the observed outcomes.

Participants will:

1. Perform either 6 weeks of resistance training or maintain an untrained lifestyle
2. Perform 2 weeks of limb immobilization induced disuse of a randomized leg
3. Perform 6 weeks of resistance training

Researchers will compare the resistance training preconditioning condition vs the non-trained condition to see if resistance training prior to a period of disuse is beneficial during the disuse period and in the return to training period on skeletal muscle size, strength, and underpinning molecular markers.


Eligibility Criteria:
Inclusion Criteria:

* Between the ages of 18-30
* Free from medical implants in lower extremity that would interfere with low-dose radiation
* Are not allergic to ultrasound gel or Lidocaine
* Have no or minimal experience with resistance training (less than 1 training session/week for a 1 year period)

Exclusion Criteria:

* Have been exposed to medically necessary radiation in the past 12 months other than dental x-rays
* Have known overt cardiovascular or metabolic disease
* Have a medical condition that would contraindicate participating in an exercise program or donating a skeletal muscle biopsy (e.g. blood clotting disorder, taking blood thinners, etc.)
* Are undergoing medical treatment for a disease that would interfere physiologically or logistically with study outcomes and/or protocols (e.g. undergoing chemotherapy and/or radiation for cancer treatment)
* Have consumed supplemental protein, creatine, and/or agents that affect hormone status (e.g. testosterone, growth hormone boosters, etc.) within the previous 2 months.
The Effect of Moxonidine on Blood Pressure and Regression of Early Target Organ Damage in Young Subjects With Abdominal Obesity and Hypertension

Obesity is a major risk factor for the development of hypertension. Based on population studies, risk estimates indicate that at least two-thirds of the prevalence of hypertension can be directly attributed to obesity. Obesity per se is commonly associated with activation of the sympathetic nervous system with a predominant increase in sympathetic outflow to the kidneys and the peripheral vasculature and there is now conclusive evidence that heightened sympathetic nerve activity is a major contributor to the elevation in blood pressure associated with obesity, particularly in young subjects. In line with these findings, dietary weight loss has repeatedly been demonstrated to result in reduced sympathetic nerve activity and lower blood pressure levels.

Several lines of evidence have well documented the significant role of SNS activation in obesity associated hypertension and target organ damage. Weight loss is the preferred treatment option for obesity and its consequences and reduces both SNS activation and blood pressure. In the real world however, weight loss maintenance is rarely achieved in obese patients highlighting the urgent need for alternative treatment strategies. Given the crucial involvement of SNS activation in various aspects of the obesity related increase in blood pressure, target organ damage and cardiovascular risk, the use of sympatho-inhibitory agents at an early stage is an obvious choice.

The investigators therefore plan to examine the effects of the centrally sympatholytic agent moxonidine on blood pressure and the morning surge in blood pressure, sympathetic activity, regression of early target organ damage (heart, kidney and endothelium), metabolic and inflammatory markers in young obese subjects with hypertension in a randomized, double-blind clinical trial with the angiotensin receptor blocker irbesartan as an active comparator to achieve similar blood pressure reductions in both groups. The investigators hypothesize that moxonidine treatment will result in significant improvements in these outcome parameters and beneficial effects beyond simple blood pressure reduction.

Findings from this study could pave the way for an early and pathophysiology- tailored treatment strategy of obesity related hypertension and its detrimental consequences.


Eligibility Criteria:
Inclusion Criteria:

* male age 18-30 years old
* presence of central obesity and hypertension
* no history of cardiovascular disease or depression
* not on any medication

Exclusion Criteria:

* history of cardiovascular disease, depression or anxiety disorder
Single Dose Study With Unlabeled Dose and 14C-labeled Microdose of PF-06700841 in Healthy Male Subjects

An open-label, fixed sequence, 2-period including a single oral dose 60 mg PF-06700841 with 14C-labeled microtracer in 1st period, and a single oral dose of 60 mg unlabeled PF-06700841 followed by intravenous administration of 14C-labeled microdose of PF-06700841 1 hour after oral dose in period 2 to characterize the absorption, disposition, metabolism and excretion of PF-06700841 and evaluate the absolute bioavailability and fraction absorbed in the GI tract


Eligibility Criteria:
Exclusion Criteria:

* Any clinically significant malabsorption condition (eg, gastrectomy, bowel resection).
* Total 14C radioactivity measured in plasma exceeding 11 mBq/mL
* History of tuberculosis or active or latent or inadequately treated infection, positive QuantiFERON®-TB Gold test
* Use of tobacoo/nicotine containing products 3-m prior to dosing or positive urine cotinine test
* Use of herbal supplements within 28 days prior to the first dose of study medication
* Use of prescription or nonprescription drugs (including vitamins and dietary supplements) within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study medication. As an exception, acetaminophen may be used at doses of 1 g/day. Limited use of non-prescription medications that are not believed to affect subject safety or the overall results of the study may be permitted on a case-by-case basis following approval by Pfizer
* Inability to have at least one bowel movement every 2 days on average eGFR of \<90 mL/mim/1.73 m2 based on MDRD equation
* Have been vaccinated with live or attenuated live vaccine within the 6 weeks prior to the first dose of investigational product, or expects to be vaccinated with these vaccines during study treatment, or within the 6 weeks following the last dose of investigational product.
Systematic Screening for Comorbid Psychological Conditions in Cardiac ACSC Patients With Multimorbidity in the ED

EMASPOT assesses the prevalence and impact of mental health conditions in multimorbid emergency patients with cardiac ACSC on transsectoral utilisation of health care services.

The specific aims of EMASPOT are primarily to determine the prevalence of mental health conditions (MHC) (i.e., symptoms of depression, anxiety, somatoform disorders, and alcohol abuse) in patients with multimorbidity and cardiac ACSC in a prospective cohort study.

The study population comprises patients admitted to an ED in Berlin-Mitte during the study period from 01.06.2017 to 31.05.2018 with cardiac complaints who are admitted to the hospital or discharged from ED. The study focusses especially on older and multimorbid patients. Multimorbidity is defined as the presence of more than two chronic diagnoses.

After having given informed consent patients are enrolled in the study and interviewed by a study nurse. Self-reported symptom burden for depression, anxiety disorders, somatoform disorders, alcohol abuse as well as frequency of utilization of health care services are assessed. Medical data will be abstracted from medical charts and include somatic comorbidities, medication and diagnostic procedures and interventions during hospitalization.

Individual semi-structured interviews will be conducted with 30 patients to assess the treatment expectations and underlying motives for ED-visits, as well as with 30 health care professionals to investigate perceptions of challenges regarding identification and treatment of patients with MHC.

All patients will have a 6-months follow-up after discharge from the ED. The follow-up is conducted either by telephone calls, e-mail or via mail. The follow-up data will include mental health conditions as assessed at baseline, frequency of utilization of health care services and health-related quality of life.

Eligibility Criteria:
Inclusion Criteria:

* Patients presenting to one of the EDs in Berlin-Mitte due to cardiac complaints (acute heart failure, angina pectoris, dyspnea, arrhythmias)
* Age 50 and older

Exclusion Criteria:

* Age 49 and younger
* Inability to give written informed consent (cognitive impairment, legal guardianship)
* Insufficient language skills to complete the questionnaire in one of the provided languages (German, English, Russian, Turkish)
Technology-Based Distractions During Minor Procedures

The purpose of this study is to determine if non-invasive distracting devices (Virtual Reality headset, Augmented Reality Headset) are more effective than the standard of care (i.e., no technology-based distraction) for decreasing anxiety and pain scores in pediatric patients undergoing various minor procedures (i.e lumbar punctures and cardiac catheterization). The anticipated primary outcome will be a reduction of overall cumulative medication and secondary outcomes include but are not limited to: physician satisfaction, discharge time, pain scores, anxiety scores, and procedure time.


Eligibility Criteria:
Inclusion Criteria:

* Age 17 and under
* Able to consent or have parental consent
* Undergoing minor procedures (i.e lumbar punctures, cardiac catheterization) at Lucile Packard Children's Hospital (LPCH) or Stanford Hospital facilities

Exclusion Criteria:

* People who do not consent
* Significant Cognitive Impairment
* History of Severe Motion Sickness
* Current Nausea
* Seizures
* Visual Problems
* Non-English Speaking
* Patients who clinically unstable or requires urgent/emergent intervention
* (ASA) Physical status classification class 4 or higher
* Patient or parental preference for General Anesthesia
Dongguan Eye Study of Schoolchildren and Adolescents（DESSA）

This is a study to report the change of ocular biometry of schoolchildren and adolescents as well as its association with birth parameters in China.


Eligibility Criteria:
Inclusion Criteria:

* Schoolchildren and adolescents aged 7 to18 years in Dongguan
* Parents are willing to sign the informed written consent.

Exclusion Criteria:

* Those without informed written consent or unable to obey the study procedures
Efficacy of Repetitive Transcranial Magnetic Stimulation (rTMS) as an add-on Treatment for Resistant OCD

OCD is a chronic condition with a high rate of poor responders to conventional treatments, such as antidepressants and psychotherapy. Chronic symptoms can lead to important social impairment and suffering for patients and families.

The present study aims to investigate if the addition of transcranial magnetic stimulation can provide enhanced response to conventional treatment.

Transcranial magnetic stimulation is a noninvasive technique that can influence specific areas of the brain and has very few side effects.

The treatment with transcranial magnetic stimulation requires attendance to hospital daily sessions for 6 consecutive weeks. Each session lasts up to 30 minutes.

Side effects include scalp discomfort and mild headache. No anesthesia is required.

Stimulation aims the dorsolateral prefrontal cortex, a region previously studied to treat depression symptoms with positive results. The present technique has never been employed in previous studies, but risks are insignificant

Eligibility Criteria:
Inclusion Criteria:

* resistant OCD patients: maximum 25% reduction in Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) scores after at least 3 adequate trials with serotonin reuptake inhibitors (SRI) (including clomipramine) and 20 hours of cognitive behavioral therapy (CBT) or documented intolerance to either treatment.

Exclusion Criteria:

* metallic cerebral implants
* history of severe trauma or brain injury
* organic brain disease
* severe somatic disease
* history of drug dependence
* chronic psychosis
* present manic state
Time Restricted Nutrition in Pediatric Stem Cell Transplant Recipients

Circadian cycles, metabolism, and nutrition are intimately linked, and the timing of meals play an important role in synchronizing peripheral circadian rhythms. There are little data describing the influence of nocturnal feeds on sleep, metabolism, and overall health in hospitalized children. To evaluate this association, the investigators will conduct a single-center, randomized, non-blinded controlled trial that will test the impact of nocturnal enteral/parenteral nutrition on patient outcomes.

HSCT provides a potential cure for children and adults with high risk and relapsed malignancy, immune deficiency, and other fatal illnesses. Circadian cycles, metabolism, and nutrition are intimately linked, and the timing of meals play an important role in synchronizing peripheral circadian rhythms; however, the standard of care for HSCT recipients is to deliver continuous feeds (either enterally or parenterally).

The objective of this study is to evaluate the influence of the timing of feeding on sleep and metabolism in HSCT subjects. The investigators hypothesize patients receiving feeds during daytime hours (0800-2000) in comparison to continuous (24 hours), will have improved sleep efficiency, decreased blood glucose, insulin, and triglycerides over patients who receive feeding overnight. The aim of this study is to evaluate the influence of the timing of feeds on sleep, metabolism, and outcomes in HSCT subjects.

Eligibility Criteria:
Inclusion Criteria:

* Patients \>/= 12 months of age undergoing HSCT and receiving a myeloablative preparative regimen

Exclusion Criteria:

* Prior history of hypoglycemia, diabetes mellitus, metabolic disease, or other requirement for continuous nutrition
Costs of Postoperative Nausea and Vomiting in Ambulatory Surgery Patients

This is an observational study with the goal of determining the costs of nausea and vomiting in ambulatory patients after surgery from the US societal perspective.

The direct cost between the end of outpatient surgery and discharge from the hospital will include costs of labors and supplies for any outpatient care, physician visits, laboratory tests, and prescribed medications, which may be used to treat operation side effects. Based on the time and motion study design, the timing of these healthcare activities will be collected. The study coordinator will observe the actual time taken for each activity for each patient. The observation period will begin after completion of the outpatient surgery. The start and end times for each activity performed will be recorded. Therefore, each activity and its duration will be concurrently recorded. We will also query patients daily to determine additional costs associated with PONV until the third postoperative morning.

Eligibility Criteria:
Inclusion Criteria:

* Male or female
* 18 years of age or older
* American Society of Anesthesiologists (ASA) physical status 1 to 3
* Outpatients undergoing elective surgery with anesthesia that is expected to last one hour and to require significant postoperative opioids
* Patients must provide written informed consent and have at least two of the following PONV risk factors: (1) female gender, (2) history of PONV and/or currently prone to motion sickness, (3) non smoking status.

Exclusion Criteria:

* Any drug with potential antiemetic efficacy within 24 hours prior to the anesthetic procedure
* Vomiting, retching, or nausea in the 24 hours preceding anesthesia
* Body mass index \>40.
Effect of Potato Fiber on Appetite and Fecal Fat Excretion

Results have indicated that some dietary fibers increase fecal fat excretion and particularly viscous fibers suppress appetite sensation and reduce energy intake. Both these effects may contribute to body weight management.

Aim: The aim of the study is to investigate the potential of 3-weeks daily intake of potato pulp (FiberBind), rhamnogalacturonan I isolated potato fiber (RG-I) vs. a low-fiber control (placebo) on satiety and fecal fat excretion in healthy adults. Furthermore, a number of secondary endpoints are investigated.


Eligibility Criteria:
Inclusion Criteria:

* Healthy Men
* BMI between 18.5 and 27.0 kg/m2
* Age 20-40 years

Exclusion Criteria:

* Intake of potatoes with main meals more frequent than 4 times per week
* Chronic diseases (known diabetes, cardiovascular disease, irritable bowels disease, colitis ulcerosa, crohn disease, or other chronic diseases which could affect the results of the present study)
* Gluten allergy
* Use of daily prescription medicine (mild analgesics are allowed)
* Use of lipid-lowering agents (e.g. Becel, HUSK)
* Use of food supplements of relevance to the study (such as pre- and probiotics)
* Irregular intake of vitamin /mineral supplements (two weeks prior to and during the entire study period)
* Smoking
* Elite athletes (\>10 hours of strenuous physical activity per week)
* Blood donation (\<1 month before study commencement and during study period)
* Participation in other clinical studies (\<1 month before study commencement and during study period)
* Inability (physically or psychologically) to comply with the procedures required by the protocol judged by the Investigator
Randomized Control Trial on Postoperative Weight Bearing After High Tibial Osteotomy (HTO)

The study analyzes the consequences of weight bearing after an HTO in a population of young patient with medial osteoarthritis (immediate weight bearing versus two month weight bearing). The two options are usually used so the protocol belongs to the intermediate care evaluation category.

The IKS (International Knee Society) score at one year follow up is the first outcome. The aim of the study is to highlight that the option early weight bearing (immediately in postoperative) is equal to the option delayed weight bearing.


Eligibility Criteria:
Inclusion Criteria:

* age: 40 to 65 years old
* patients with medial osteoarthritis of knee of level 1 or 2 from ahlback's classification with High Tibial Osteotomy indication
* one sided indication
* well understanding of information note by patient, non-opposition to perform the research
* Affiliation to a national health insurance program

Exclusion Criteria:

* age \< 40 or \> 65 years old
* medial osteoarthritis of knee of level superior to 2
* bilatéral indication
* patient opposition
* non affiliation to a national health insurance program
* law protected patients
* pregnancy and breast feeding
Young Adult Beverage and Health Study

This study examines the impact of health signage on beverage consumption in a cafeteria.


Eligibility Criteria:
Inclusion Criteria:

* Undergraduate student or staff member at specific university
* Age 18+
* On meal plan if a student
* Works in specific cafeterias if staff

Exclusion Criteria:

* Age \<18 years
* Adults unable to consent or complete the written or online survey
Fatigue One Year After ICU Discharge

The investigators contacted consecutive adult patients admitted to intensive care unit (ICU) and mechanically ventilated for at least 72 hours to invite them to an interview at hospital. The investigators administered Mini Mental Status Examination, Functional Assessment of Chronic Illness Therapy scale for Fatigue (Facit- F) and Short form 36 questionnaires to the consenting patients.

Fatigue is one of the most commonly symptoms reported by patients. There are many causes of pathological fatigue including mental and physical, both neurological (central and peripheral) and non-neurological diseases. Among the last ones, cancer, infections and drugs are factors associated with fatigue, although the mechanism of how non-neurological diseases cause fatigue is not clear. Evidence exists to suggest that patients who have been critically ill continue to face a multitude of physical, psychological and social difficulties in the long term after discharge. As far as fatigue is concerned, greater than 50% of Intensive Care Unit survivors overall reported lowered energy levels and fatigue in the first year after discharge.

Eligibility Criteria:
Inclusion Criteria:

* aged \> 18 years
* able to co-operate at the time of ICU discharge
* requiring mechanical ventilation for at least 72 hours
* residents less than 30 km from the hospital

Exclusion Criteria:

* preexisting cognitive deficits
* pre-existing psychotic illness
* admitted for anoxic brain injury
* residents more than 30 km from the hospital